Neurocrine Gains Clinical-Stage Schizophrenia Candidates Returned To Sosei By AbbVie
Executive Summary
Deal Snapshot: Neurocrine expanded its pipeline with rights to subtype-selective muscarinic M4, M1 and dual M1/M4 receptor agonists discovered by Sosei.
You may also be interested in...
Sosei Bolsters GPCR Focus With AbbVie Neurology Deal
The Japanese firm has expanded its partnership with AbbVie into the neurology space, where it hopes to use its unique platform technology to develop up to three drug candidates targeting ‘challenging’ G protein-coupled receptor targets.
Return Of In-Person Psychiatry Visits Could Lift Neurocrine’s Ingrezza
Ingrezza became a $1bn therapy in 2022 despite the pandemic, but Neurocrine expect many more patients are diagnosed and treated if the pandemic eases as hoped.
Neurocrine Closer To Ingrezza Label Expansion With Huntington’s Chorea Phase III Win
The neuroscience-focused firm plans a 2022 supplemental NDA for Ingrezza following success in the pivotal KINECT-HD study. The biotech needed an R&D success after recent stumbles.